Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue
+1.33%
EPS
+418.2%
Free cash flow
−6.83%
Total debt
−42.2%

Quarter to June 2026, against a year earlier

72.76 0.10 +0.14%
Market cap
$11.4B
P/E
62.2×
Fwd P/E
54.2×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100

Bio-Techne Corp (TECH) Current ratio

Alert me on Current ratio

Bio-Techne Corp's current ratio at the end of the quarter to 30 June 2026 was 4.5×. Over the past ten years it has ranged from 2.6× (fiscal 2017) to 6.2× (fiscal 2015); the current reading is higher than 58% of that period. That is below the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2026 4.5× 31.46%
FY2025 3.5× (10.70%)
FY2024 3.9× (19.90%)
FY2023 4.8× 40.57%
FY2022 3.4× 2.60%
FY2021 3.4× (31.34%)
FY2020 4.9× 20.71%
FY2019 4.0× (19.25%)
FY2018 5.0× 95.11%
FY2017 2.6× (45.23%)

Quarterly newest first

Period Current ratio Change
Jun 2026 4.5× 1.30%
Mar 2026 4.5× (1.11%)
Dec 2025 4.5× 7.65%
Sep 2025 4.2× 21.90%
42 more quarters

Against its own ten years

Low 2.6× High 6.2×
Ten-year median 4.3×
Current reading's percentile 58

Current ratio against peers

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on TECH